Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and POF in advanced gastric cancer
NCT03244774Phase 1Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Rivoceranib in gastric adenocarcinoma, sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Dose-Limiting Toxicity at 4 weeks and Maximum Tolerated Dose at 12 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03244774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244774.